588 related articles for article (PubMed ID: 19679216)
1. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study.
Phua KB; Lim FS; Lau YL; Nelson EA; Huang LM; Quak SH; Lee BW; Teoh YL; Tang H; Boudville I; Oostvogels LC; Suryakiran PV; Smolenov IV; Han HH; Bock HL
Vaccine; 2009 Oct; 27(43):5936-41. PubMed ID: 19679216
[TBL] [Abstract][Full Text] [Related]
2. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials.
De Vos B; Han HH; Bouckenooghe A; Debrus S; Gillard P; Ward R; Cheuvart B
Pediatr Infect Dis J; 2009 Apr; 28(4):261-6. PubMed ID: 19289978
[TBL] [Abstract][Full Text] [Related]
3. Update on Rotarix: an oral human rotavirus vaccine.
O'Ryan M; Linhares AC
Expert Rev Vaccines; 2009 Dec; 8(12):1627-41. PubMed ID: 19943758
[TBL] [Abstract][Full Text] [Related]
4. A short report on highlights of world-wide development of RIX4414: a Latin American experience.
Linhares AC; Ruiz-Palacios GM; Guerrero ML; Salinas B; Perez-Schael I; Clemens SA; Innis B; Yarzabal JP; Vespa G; Cervantes Y; Hardt K; De Vos B
Vaccine; 2006 May; 24(18):3784-5. PubMed ID: 16098636
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study.
Linhares AC; Velázquez FR; Pérez-Schael I; Sáez-Llorens X; Abate H; Espinoza F; López P; Macías-Parra M; Ortega-Barría E; Rivera-Medina DM; Rivera L; Pavía-Ruz N; Nuñez E; Damaso S; Ruiz-Palacios GM; De Vos B; O'Ryan M; Gillard P; Bouckenooghe A;
Lancet; 2008 Apr; 371(9619):1181-9. PubMed ID: 18395579
[TBL] [Abstract][Full Text] [Related]
7. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants.
Ruiz-Palacios GM; Guerrero ML; Bautista-Márquez A; Ortega-Gallegos H; Tuz-Dzib F; Reyes-González L; Rosales-Pedraza G; Martínez-López J; Castañón-Acosta E; Cervantes Y; Costa-Clemens S; DeVos B
Pediatrics; 2007 Aug; 120(2):e253-61. PubMed ID: 17606534
[TBL] [Abstract][Full Text] [Related]
8. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa.
Tapia MD; Armah G; Breiman RF; Dallas MJ; Lewis KD; Sow SO; Rivers SB; Levine MM; Laserson KF; Feikin DR; Victor JC; Ciarlet M; Neuzil KM; Steele AD
Vaccine; 2012 Apr; 30 Suppl 1():A79-85. PubMed ID: 22520141
[TBL] [Abstract][Full Text] [Related]
9. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.
Omenaca F; Sarlangue J; Szenborn L; Nogueira M; Suryakiran PV; Smolenov IV; Han HH;
Pediatr Infect Dis J; 2012 May; 31(5):487-93. PubMed ID: 22228231
[TBL] [Abstract][Full Text] [Related]
10. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants.
Bernstein DI; Sack DA; Reisinger K; Rothstein E; Ward RL
J Infect Dis; 2002 Nov; 186(10):1487-9. PubMed ID: 12404166
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study.
Vesikari T; Karvonen A; Prymula R; Schuster V; Tejedor JC; Cohen R; Meurice F; Han HH; Damaso S; Bouckenooghe A
Lancet; 2007 Nov; 370(9601):1757-63. PubMed ID: 18037080
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial.
Madhi SA; Kirsten M; Louw C; Bos P; Aspinall S; Bouckenooghe A; Neuzil KM; Steele AD
Vaccine; 2012 Apr; 30 Suppl 1():A44-51. PubMed ID: 22520136
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.
Goveia MG; Rodriguez ZM; Dallas MJ; Itzler RF; Boslego JW; Heaton PM; DiNubile MJ;
Pediatr Infect Dis J; 2007 Dec; 26(12):1099-104. PubMed ID: 18043445
[TBL] [Abstract][Full Text] [Related]
14. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine.
Breiman RF; Zaman K; Armah G; Sow SO; Anh DD; Victor JC; Hille D; Ciarlet M; Neuzil KM
Vaccine; 2012 Apr; 30 Suppl 1():A24-9. PubMed ID: 22520132
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.
Armah GE; Sow SO; Breiman RF; Dallas MJ; Tapia MD; Feikin DR; Binka FN; Steele AD; Laserson KF; Ansah NA; Levine MM; Lewis K; Coia ML; Attah-Poku M; Ojwando J; Rivers SB; Victor JC; Nyambane G; Hodgson A; Schödel F; Ciarlet M; Neuzil KM
Lancet; 2010 Aug; 376(9741):606-14. PubMed ID: 20692030
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.
Zaman K; Dang DA; Victor JC; Shin S; Yunus M; Dallas MJ; Podder G; Vu DT; Le TP; Luby SP; Le HT; Coia ML; Lewis K; Rivers SB; Sack DA; Schödel F; Steele AD; Neuzil KM; Ciarlet M
Lancet; 2010 Aug; 376(9741):615-23. PubMed ID: 20692031
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life.
Kawamura N; Tokoeda Y; Oshima M; Okahata H; Tsutsumi H; Van Doorn LJ; Muto H; Smolenov I; Suryakiran PV; Han HH
Vaccine; 2011 Aug; 29(37):6335-41. PubMed ID: 21640780
[TBL] [Abstract][Full Text] [Related]
18. The human rotavirus vaccine RIX4414 in infants: a review of safety and tolerability.
Cheuvart B; Friedland LR; Abu-Elyazeed R; Han HH; Guerra Y; Verstraeten T
Pediatr Infect Dis J; 2009 Mar; 28(3):225-32. PubMed ID: 19209095
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants.
Steele AD; Reynders J; Scholtz F; Bos P; de Beer MC; Tumbo J; Van der Merwe CF; Delem A; De Vos B
J Infect Dis; 2010 Sep; 202 Suppl():S93-100. PubMed ID: 20684724
[TBL] [Abstract][Full Text] [Related]
20. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.
Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF
Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
